[
  {
    "id": "biomarker-ferritin-001",
    "text_summary": "Serum ferritin measured within 72h of CAR-T infusion is a strong predictor of severe cytokine release syndrome. In the ELIANA trial, patients developing grade 3-4 CRS had median peak ferritin of 69,640 ng/mL versus 4,286 ng/mL in grade 0-2 CRS (p<0.001). A pre-infusion ferritin >500 ng/mL combined with rising trajectory identifies high-risk patients requiring closer monitoring. PMID:29385376.",
    "biomarker_name": "Ferritin",
    "biomarker_type": "predictive",
    "assay_method": "Immunoturbidimetry",
    "clinical_cutoff": ">500 ng/mL pre-infusion; peak >10,000 ng/mL",
    "predictive_value": "PPV 78%, NPV 85% for grade 3+ CRS",
    "associated_outcome": "Cytokine release syndrome severity",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-crp-002",
    "text_summary": "C-reactive protein is an acute-phase reactant that rises early in cytokine release syndrome and serves as an accessible clinical biomarker. In tisagenlecleucel-treated patients, CRP >20 mg/dL within 36h post-infusion predicted grade >=3 CRS with 86% sensitivity. CRP kinetics parallel IL-6 elevation but are more rapidly available in most hospital laboratories. Serial monitoring every 12h is recommended during the at-risk period (days 1-10). PMID:28622514.",
    "biomarker_name": "CRP",
    "biomarker_type": "predictive",
    "assay_method": "Latex-enhanced immunoturbidimetry",
    "clinical_cutoff": ">20 mg/dL within 36h post-infusion",
    "predictive_value": "Sensitivity 86%, specificity 64% for grade 3+ CRS",
    "associated_outcome": "Early CRS detection and grading",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-il6-003",
    "text_summary": "Interleukin-6 is the central cytokine mediating CRS pathophysiology and the therapeutic target of tocilizumab. Peak IL-6 levels >1,000 pg/mL correlate with grade 3-4 CRS requiring ICU-level intervention. In the ZUMA-1 trial, median peak IL-6 was 1,689.5 pg/mL in severe CRS vs 51.1 pg/mL in mild CRS. IL-6 measurement guides tocilizumab administration decisions. PMID:28622514.",
    "biomarker_name": "IL-6",
    "biomarker_type": "predictive",
    "assay_method": "ELISA",
    "clinical_cutoff": ">1,000 pg/mL",
    "predictive_value": "PPV 82% for grade 3+ CRS when combined with ferritin",
    "associated_outcome": "CRS severity and tocilizumab intervention timing",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-il10-004",
    "text_summary": "Interleukin-10 is an immunosuppressive cytokine that paradoxically rises during severe CRS and may reflect macrophage hyperactivation. Elevated IL-10 >60 pg/mL within 48h of CAR-T infusion has been associated with concurrent neurotoxicity (ICANS) in addition to CRS. IL-10 elevation distinguishes CRS-only from CRS+ICANS phenotypes, enabling risk-adapted management strategies. PMID:31235964.",
    "biomarker_name": "IL-10",
    "biomarker_type": "predictive",
    "assay_method": "Luminex multiplex",
    "clinical_cutoff": ">60 pg/mL within 48h post-infusion",
    "predictive_value": "PPV 71%, NPV 89% for concurrent ICANS",
    "associated_outcome": "Combined CRS and neurotoxicity prediction",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-sil2r-005",
    "text_summary": "Soluble interleukin-2 receptor (sIL-2R/sCD25) reflects T-cell activation intensity and is elevated in hemophagocytic lymphohistiocytosis (HLH)-like toxicity following CAR-T therapy. sIL-2R >2,500 U/mL at day 3 post-infusion identifies patients at risk for fulminant HLH/macrophage activation syndrome, a life-threatening complication overlapping with severe CRS. This biomarker helps differentiate CRS from CAR-T-associated HLH. PMID:30409789.",
    "biomarker_name": "sIL-2R",
    "biomarker_type": "predictive",
    "assay_method": "ELISA",
    "clinical_cutoff": ">2,500 U/mL",
    "predictive_value": "PPV 74% for HLH-like syndrome post-CAR-T",
    "associated_outcome": "HLH/macrophage activation syndrome risk",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-cmax-006",
    "text_summary": "Peak CAR-T cell expansion (Cmax) in peripheral blood is the strongest pharmacokinetic predictor of durable response. In ZUMA-1, patients achieving CR/CRi had median peak expansion of 113.7 cells/uL vs 21.8 cells/uL in non-responders (p<0.001). Cmax >50 cells/uL within 7-14 days post-infusion is associated with >70% probability of month-3 complete response. Measured by flow cytometry or qPCR for transgene. PMID:28622514.",
    "biomarker_name": "CAR-T Peak Expansion (Cmax)",
    "biomarker_type": "predictive",
    "assay_method": "Flow cytometry",
    "clinical_cutoff": ">50 CAR-T cells/uL in peripheral blood",
    "predictive_value": "PPV 73% for month-3 CR",
    "associated_outcome": "Complete response at day 90",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-tcell-fitness-007",
    "text_summary": "Pre-manufacturing T-cell fitness, assessed by mitochondrial spare respiratory capacity and proliferative index, predicts CAR-T product quality and clinical efficacy. Patients whose leukapheresis T-cells demonstrate proliferative index >3.5 upon anti-CD3/CD28 stimulation produce CAR-T products with superior in vivo expansion. Low T-cell fitness correlates with prior lines of therapy (>3) and predicts manufacturing failure or poor expansion. PMID:33046569.",
    "biomarker_name": "T-cell Fitness Score",
    "biomarker_type": "predictive",
    "assay_method": "Seahorse metabolic assay and CFSE proliferation",
    "clinical_cutoff": "Proliferative index >3.5",
    "predictive_value": "PPV 68% for successful manufacturing and in vivo expansion",
    "associated_outcome": "Manufacturing success and in vivo expansion",
    "target_antigen": "",
    "disease": "B-ALL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-tcm-pct-008",
    "text_summary": "The percentage of central memory T-cells (Tcm, CD45RO+CCR7+) in leukapheresis product predicts long-term CAR-T persistence and durable remission. In tisagenlecleucel studies, patients with >40% Tcm in pre-manufacture apheresis product had significantly longer B-cell aplasia duration (median 18 vs 6 months, p=0.003), reflecting superior CAR-T persistence. Tcm enrichment strategies during manufacturing can improve outcomes for patients with low baseline Tcm%. PMID:29385376.",
    "biomarker_name": "Tcm%",
    "biomarker_type": "predictive",
    "assay_method": "Flow cytometry (CD45RO+CCR7+CD62L+)",
    "clinical_cutoff": ">40% Tcm in apheresis product",
    "predictive_value": "PPV 65% for durable response >=12 months",
    "associated_outcome": "CAR-T persistence and durable remission",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-cd4cd8-ratio-009",
    "text_summary": "The CD4:CD8 ratio in the infused CAR-T product influences both efficacy and toxicity profiles. Products with CD4:CD8 ratio between 1:1 and 1:3 show optimal anti-tumor activity with manageable toxicity. Lisocabtagene maraleucel (liso-cel) is manufactured at a defined 1:1 CD4:CD8 ratio, which contributed to a lower severe CRS rate (2%) compared to non-defined composition products (13-22%). PMID:32888407.",
    "biomarker_name": "CD4:CD8 Ratio",
    "biomarker_type": "predictive",
    "assay_method": "Flow cytometry",
    "clinical_cutoff": "Optimal range 1:1 to 1:3",
    "predictive_value": "Defined 1:1 composition associated with 2% grade 3+ CRS rate",
    "associated_outcome": "Balanced efficacy-toxicity profile",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-ldh-010",
    "text_summary": "Pre-lymphodepletion serum lactate dehydrogenase (LDH) reflects tumor burden and metabolic activity, serving as a robust prognostic marker for CAR-T outcomes. In ZUMA-1, patients with baseline LDH >ULN had inferior ORR (72% vs 91%) and shorter median PFS (3.1 vs 15.4 months). LDH >2x ULN identifies ultra-high-risk patients who may benefit from bridging therapy to reduce tumor burden prior to CAR-T infusion. PMID:28622514.",
    "biomarker_name": "LDH",
    "biomarker_type": "prognostic",
    "assay_method": "Spectrophotometry (L-to-P reaction)",
    "clinical_cutoff": ">2x upper limit of normal (ULN)",
    "predictive_value": "LDH >ULN: ORR 72% vs 91% (p=0.01)",
    "associated_outcome": "Overall response rate and progression-free survival",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-pd1-011",
    "text_summary": "Programmed death-1 (PD-1) expression on CAR-T cells increases following chronic antigen stimulation and marks functionally exhausted cells with impaired cytotoxicity. PD-1+ CAR-T cells >50% in the infusion product correlate with reduced peak expansion and shorter remission duration. Combinatorial approaches with PD-1 blockade (pembrolizumab) post-CAR-T have shown preliminary efficacy in rescuing exhausted CAR-T cells in refractory DLBCL. PMID:28187457.",
    "biomarker_name": "PD-1 (CD279)",
    "biomarker_type": "resistance",
    "assay_method": "Flow cytometry",
    "clinical_cutoff": ">50% PD-1+ in CAR-T product",
    "predictive_value": "PPV 62% for early relapse (<6 months)",
    "associated_outcome": "CAR-T functional exhaustion and reduced persistence",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-lag3-012",
    "text_summary": "Lymphocyte activation gene-3 (LAG-3) is an inhibitory receptor upregulated on exhausted T-cells that binds MHC-II with higher affinity than CD4. Co-expression of LAG-3 with PD-1 on CAR-T cells defines a deeply exhausted population with minimal residual cytolytic function. LAG-3+PD-1+ dual-positive CAR-T cells >30% in post-infusion samples predict treatment failure. LAG-3 knockout CAR-T constructs are in clinical development. PMID:31784374.",
    "biomarker_name": "LAG-3 (CD223)",
    "biomarker_type": "resistance",
    "assay_method": "Flow cytometry (multi-color panel)",
    "clinical_cutoff": ">30% LAG-3+PD-1+ dual-positive CAR-T cells",
    "predictive_value": "PPV 70% for treatment failure when co-expressed with PD-1",
    "associated_outcome": "Deep functional exhaustion and non-response",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-tim3-013",
    "text_summary": "T-cell immunoglobulin and mucin domain-3 (TIM-3) is a terminal exhaustion marker that identifies CAR-T cells refractory to reinvigoration by checkpoint blockade. TIM-3 expression on circulating CAR-T cells at day 14 post-infusion inversely correlates with response durability. Triple-positive PD-1+LAG-3+TIM-3+ CAR-T cells represent an irreversibly exhausted population. TIM-3 blocking antibodies combined with CAR-T therapy are under investigation. PMID:33504555.",
    "biomarker_name": "TIM-3 (HAVCR2)",
    "biomarker_type": "resistance",
    "assay_method": "Flow cytometry",
    "clinical_cutoff": ">25% TIM-3+ in circulating CAR-T cells at day 14",
    "predictive_value": "Inverse correlation with response duration (r = -0.58, p=0.003)",
    "associated_outcome": "Terminal CAR-T exhaustion and relapse risk",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-tox-014",
    "text_summary": "Thymocyte selection-associated HMG box protein (TOX) is a transcription factor that drives the epigenetic program of T-cell exhaustion. High TOX expression in CAR-T products correlates with chromatin remodeling at exhaustion-associated gene loci, rendering cells resistant to functional rescue. TOX-high CAR-T cells show reduced granzyme B production and impaired serial killing capacity. CRISPR-mediated TOX knockout in CAR-T cells improves anti-tumor function in preclinical models. PMID:31207603.",
    "biomarker_name": "TOX",
    "biomarker_type": "resistance",
    "assay_method": "Intracellular flow cytometry / RT-qPCR",
    "clinical_cutoff": "TOX MFI >2x isotype control",
    "predictive_value": "High TOX associated with 3.2-fold reduced serial killing capacity",
    "associated_outcome": "Epigenetic exhaustion programming and impaired effector function",
    "target_antigen": "",
    "disease": "B-NHL",
    "evidence_level": "exploratory"
  },
  {
    "id": "biomarker-nr4a-015",
    "text_summary": "NR4A family transcription factors (NR4A1, NR4A2, NR4A3) are key drivers of CAR-T cell dysfunction that act downstream of chronic TCR/CAR signaling. Triple NR4A knockout (NR4A TKO) CAR-T cells demonstrate enhanced tumor rejection and prolonged survival in murine models of B-cell malignancies. NR4A expression in the infused product serves as a surrogate for tonic signaling-induced exhaustion during manufacturing. PMID:31207604.",
    "biomarker_name": "NR4A (NR4A1/2/3)",
    "biomarker_type": "resistance",
    "assay_method": "RT-qPCR / RNA-seq",
    "clinical_cutoff": "NR4A1 expression >5-fold above resting T-cells",
    "predictive_value": "NR4A-high products associated with 45% lower ORR in preclinical models",
    "associated_outcome": "Tonic signaling-driven exhaustion and reduced anti-tumor efficacy",
    "target_antigen": "",
    "disease": "B-NHL",
    "evidence_level": "exploratory"
  },
  {
    "id": "biomarker-mrd-flow-016",
    "text_summary": "Multiparameter flow cytometry (MFC) for minimal residual disease (MRD) detection achieves sensitivity of 10^-4 and is the standard for early response assessment post-CAR-T in B-ALL. MRD negativity by flow at day 28 post-infusion is a strong predictor of event-free survival, with MRD-negative patients having 2-year EFS of 62% vs 12% for MRD-positive patients. The EuroFlow NGF panel with >=8 colors is recommended for optimal sensitivity. PMID:29785878.",
    "biomarker_name": "Flow Cytometry MRD",
    "biomarker_type": "monitoring",
    "assay_method": "Multiparameter flow cytometry (>=8-color)",
    "clinical_cutoff": "<10^-4 (MRD negative)",
    "predictive_value": "MRD-neg day 28: 2-year EFS 62% vs 12% MRD-pos",
    "associated_outcome": "Event-free survival post-CAR-T",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-mrd-pcr-017",
    "text_summary": "PCR-based MRD detection using patient-specific immunoglobulin gene rearrangements (IgH/IgK) provides sensitivity of 10^-5 to 10^-6, superior to flow cytometry. In post-CAR-T B-ALL monitoring, PCR MRD negativity at 3 months correlates with sustained molecular remission. Next-generation sequencing (NGS)-based MRD platforms (e.g., ClonoSEQ) offer standardized quantification and are FDA-cleared for MRD assessment. PMID:30385432.",
    "biomarker_name": "PCR/NGS MRD",
    "biomarker_type": "monitoring",
    "assay_method": "NGS-based IgH rearrangement (ClonoSEQ)",
    "clinical_cutoff": "<10^-6 (deep molecular remission)",
    "predictive_value": "NGS MRD-neg at 3 months: 80% sustained remission at 12 months",
    "associated_outcome": "Deep molecular remission and long-term disease control",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-ctdna-018",
    "text_summary": "Circulating tumor DNA (ctDNA) enables non-invasive monitoring of molecular relapse post-CAR-T therapy in lymphoma. Detectable ctDNA at day 28 by cancer personalized profiling by deep sequencing (CAPP-Seq) predicts PFS with hazard ratio 4.2 (p<0.001). ctDNA clearance kinetics within the first 14 days correlate with best overall response. ctDNA molecular relapse precedes radiographic progression by a median of 3.5 months. PMID:34185073.",
    "biomarker_name": "ctDNA",
    "biomarker_type": "monitoring",
    "assay_method": "CAPP-Seq / Phased variant enrichment",
    "clinical_cutoff": "Undetectable (<2.5 copies/mL plasma)",
    "predictive_value": "Day 28 ctDNA+: HR 4.2 for progression (p<0.001)",
    "associated_outcome": "Molecular relapse detection and progression-free survival",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-bcell-recovery-019",
    "text_summary": "Recovery of normal CD19+ B-cells in peripheral blood after CAR-T therapy is a surrogate marker of CAR-T cell loss and potential disease relapse. Persistent B-cell aplasia indicates ongoing functional CAR-T surveillance. B-cell recovery (>1% CD19+ B-cells of lymphocytes) before 6 months post-infusion is associated with increased relapse risk (HR 3.8). Monitoring by flow cytometry every 4-6 weeks guides IVIG replacement and relapse surveillance. PMID:29785878.",
    "biomarker_name": "B-cell Recovery",
    "biomarker_type": "monitoring",
    "assay_method": "Flow cytometry (CD19/CD20 enumeration)",
    "clinical_cutoff": ">1% CD19+ B-cells of total lymphocytes",
    "predictive_value": "Early B-cell recovery (<6 months): HR 3.8 for relapse",
    "associated_outcome": "CAR-T persistence surrogate and relapse risk",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-persistence-020",
    "text_summary": "Long-term CAR-T cell persistence assessed by flow cytometry or qPCR at 6 and 12 months post-infusion is the strongest predictor of durable remission. In the ELIANA trial, detectable tisagenlecleucel at 12 months was associated with 100% sustained remission at that timepoint. Products with 4-1BB costimulatory domains show superior persistence (median >12 months) compared to CD28 domains (median 2-3 months). PMID:29385376.",
    "biomarker_name": "CAR-T Persistence",
    "biomarker_type": "pharmacodynamic",
    "assay_method": "Flow cytometry and qPCR for transgene",
    "clinical_cutoff": "Detectable CAR-T cells at >=6 months post-infusion",
    "predictive_value": "Detectable at 12 months: 100% sustained CR in ELIANA",
    "associated_outcome": "Durable remission and long-term disease control",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-transgene-copies-021",
    "text_summary": "Quantitative PCR measurement of CAR transgene copies per microgram of genomic DNA provides precise pharmacokinetic data for CAR-T expansion, contraction, and persistence phases. Peak transgene levels (typically day 7-14) of >=10^5 copies/ug DNA are associated with CR in B-ALL. The assay uses vector-specific primer/probe sets targeting the scFv-hinge junction and is the reference standard for cross-platform CAR-T quantification. PMID:28622514.",
    "biomarker_name": "Transgene Copies (qPCR)",
    "biomarker_type": "pharmacodynamic",
    "assay_method": "qPCR (TaqMan, vector-specific primers)",
    "clinical_cutoff": ">=10^5 copies/ug genomic DNA at peak",
    "predictive_value": "Peak >=10^5: 85% CR rate vs 45% below threshold",
    "associated_outcome": "CAR-T expansion kinetics and response prediction",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-auc028-022",
    "text_summary": "Area under the curve from day 0 to day 28 (AUC0-28d) of CAR-T cells integrates expansion magnitude and duration, providing a composite pharmacokinetic measure superior to Cmax alone. In axi-cel treated DLBCL patients, AUC0-28d above the median was associated with ORR of 89% vs 64% (p=0.01) and longer duration of response. AUC0-28d is calculated from serial blood draws at days 0, 7, 14, 21, and 28 using the trapezoidal rule. PMID:32888407.",
    "biomarker_name": "AUC0-28d",
    "biomarker_type": "pharmacodynamic",
    "assay_method": "Serial flow cytometry + trapezoidal calculation",
    "clinical_cutoff": "Above population median (product-specific)",
    "predictive_value": "Above-median AUC0-28d: ORR 89% vs 64% (p=0.01)",
    "associated_outcome": "Overall response rate and duration of response",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-bcell-aplasia-duration-023",
    "text_summary": "Duration of B-cell aplasia (BCA) post-CAR-T therapy serves as a functional readout of ongoing CAR-T immune surveillance. BCA duration >=6 months is associated with lower cumulative incidence of CD19+ relapse (8% vs 42% at 1 year). Median BCA duration varies by product: tisagenlecleucel ~6-12 months, axi-cel ~3-9 months, reflecting costimulatory domain differences. Requires monthly CD19+ B-cell monitoring by flow cytometry and concurrent IVIG supplementation. PMID:29785878.",
    "biomarker_name": "B-cell Aplasia Duration",
    "biomarker_type": "pharmacodynamic",
    "assay_method": "Flow cytometry (monthly CD19 enumeration)",
    "clinical_cutoff": ">=6 months of B-cell aplasia",
    "predictive_value": "BCA >=6 months: 1-year CD19+ relapse 8% vs 42%",
    "associated_outcome": "Functional CAR-T persistence and relapse prevention",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-antigen-density-024",
    "text_summary": "Target antigen density on tumor cells (molecules per cell by quantitative flow cytometry) is a critical determinant of CAR-T efficacy. CD19 density below ~1,500 molecules/cell is associated with antigen-dim relapse post-CAR-T. BCMA surface density on myeloma cells varies 10-fold between patients and correlates with CAR-T response depth. Low antigen density enables tumor escape below the CAR activation threshold. PMID:34185073.",
    "biomarker_name": "Target Antigen Density",
    "biomarker_type": "resistance",
    "assay_method": "Quantitative flow cytometry (QuantiBRITE)",
    "clinical_cutoff": "CD19 <1,500 molecules/cell; BCMA <500 molecules/cell",
    "predictive_value": "Low density associated with 3.5-fold increased antigen-escape relapse risk",
    "associated_outcome": "Antigen-dim/negative relapse mechanism",
    "target_antigen": "CD19",
    "disease": "B-ALL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-tumor-burden-025",
    "text_summary": "Pre-infusion tumor burden measured by volumetric metabolic tumor volume (MTV) on PET/CT or bone marrow blast percentage is a strong prognostic factor for CAR-T outcomes. In DLBCL, baseline MTV >80 cm3 is associated with inferior PFS (HR 2.8). In B-ALL, marrow blasts >50% pre-lymphodepletion predict higher CRS rates and lower CR durability. Bridging therapy to reduce tumor burden below thresholds may improve outcomes. PMID:34185073.",
    "biomarker_name": "Tumor Burden (MTV)",
    "biomarker_type": "prognostic",
    "assay_method": "PET/CT volumetric analysis / bone marrow biopsy",
    "clinical_cutoff": "MTV >80 cm3 (DLBCL); blasts >50% (B-ALL)",
    "predictive_value": "MTV >80 cm3: HR 2.8 for progression",
    "associated_outcome": "Progression-free survival and CRS risk",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-sbcma-026",
    "text_summary": "Soluble BCMA (sBCMA) is shed from myeloma cell surfaces by gamma-secretase and competes with membrane BCMA for CAR-T binding, potentially acting as a decoy. Baseline sBCMA >40 ng/mL is associated with reduced BCMA CAR-T response rates. In the KarMMa trial of ide-cel, sBCMA levels declined >50% from baseline in 92% of responders vs 38% of non-responders by day 28. Serial sBCMA monitoring tracks disease response and can detect early relapse. PMID:33626295.",
    "biomarker_name": "Soluble BCMA (sBCMA)",
    "biomarker_type": "resistance",
    "assay_method": "ELISA",
    "clinical_cutoff": ">40 ng/mL baseline; >50% decline indicates response",
    "predictive_value": ">50% sBCMA decline: 92% responders vs 38% non-responders",
    "associated_outcome": "BCMA CAR-T response and relapse monitoring",
    "target_antigen": "BCMA",
    "disease": "Multiple Myeloma",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-tme-immunosuppression-027",
    "text_summary": "Tumor microenvironment (TME) immunosuppression assessed by regulatory T-cell (Treg) infiltration, myeloid-derived suppressor cell (MDSC) frequency, and TGF-beta/IL-10 levels predicts CAR-T efficacy in solid tumor-like lymphoma sites. High CD4+FOXP3+ Treg infiltration (>15% of TILs) in pre-treatment biopsies is associated with impaired CAR-T trafficking and function. TME reprogramming strategies including checkpoint combinations are being explored. PMID:33504555.",
    "biomarker_name": "TME Immunosuppression Score",
    "biomarker_type": "resistance",
    "assay_method": "Multiplex IHC (Vectra) / CyTOF",
    "clinical_cutoff": "Treg >15% of TILs; MDSC >10% of myeloid cells",
    "predictive_value": "High TME suppression: ORR 35% vs 72% (low suppression)",
    "associated_outcome": "CAR-T trafficking impairment and treatment resistance",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "exploratory"
  },
  {
    "id": "biomarker-cd8tcm-product-028",
    "text_summary": "The percentage of CD8+ central memory T-cells (CD8+CD45RA-CCR7+) in the final CAR-T product is a key release criterion linked to clinical efficacy. CD8+ Tcm% >20% in the infusion product is associated with superior in vivo expansion (median 3.5-fold higher Cmax) and longer persistence. Manufacturing protocols incorporating IL-7/IL-15 during ex vivo expansion enrich Tcm phenotype compared to IL-2-based culture. PMID:33046569.",
    "biomarker_name": "CD8+ Tcm% in Product",
    "biomarker_type": "predictive",
    "assay_method": "Flow cytometry (CD8+CD45RA-CCR7+CD62L+)",
    "clinical_cutoff": ">20% CD8+ Tcm in final product",
    "predictive_value": "CD8+ Tcm >20%: 3.5-fold higher in vivo Cmax",
    "associated_outcome": "In vivo expansion magnitude and persistence",
    "target_antigen": "",
    "disease": "B-ALL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-viability-029",
    "text_summary": "Cell viability of the final CAR-T product is a critical lot-release specification. FDA guidance requires >=70% viability for infusion. Products with viability >90% show significantly better clinical outcomes: higher Cmax (p=0.008), higher ORR (88% vs 62% for 70-80% viability), and lower infusion-related reactions. Viability loss during cryopreservation and thaw accounts for the majority of post-manufacture attrition. PMID:29385376.",
    "biomarker_name": "Product Viability",
    "biomarker_type": "predictive",
    "assay_method": "Trypan blue exclusion / Automated cell counter (Vi-CELL)",
    "clinical_cutoff": ">=70% (release); >90% (optimal)",
    "predictive_value": "Viability >90%: ORR 88% vs 62% (70-80%)",
    "associated_outcome": "Product potency and clinical response rate",
    "target_antigen": "",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-vcn-030",
    "text_summary": "Vector copy number (VCN) per transduced cell quantifies the average number of integrated CAR transgene copies and is a key safety and potency metric. FDA recommends VCN <=5 copies/cell to mitigate insertional mutagenesis risk. VCN between 1-3 copies/cell provides optimal efficacy without excess toxicity. VCN <0.5 indicates poor transduction efficiency and may result in insufficient CAR expression for tumor killing. Measured by ddPCR against a reference gene. PMID:30409789.",
    "biomarker_name": "Vector Copy Number (VCN)",
    "biomarker_type": "monitoring",
    "assay_method": "Digital droplet PCR (ddPCR)",
    "clinical_cutoff": "1-3 copies/cell (optimal); <=5 (safety limit)",
    "predictive_value": "VCN 1-3: balanced efficacy-safety; VCN >5: increased insertional risk",
    "associated_outcome": "Manufacturing quality, potency, and insertional mutagenesis risk",
    "target_antigen": "",
    "disease": "B-ALL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-cd4cd8-product-031",
    "text_summary": "The CD4:CD8 T-cell ratio in the manufactured CAR-T product reflects composition balance and influences clinical performance. Liso-cel's defined 1:1 CD4:CD8 composition contributes to consistent pharmacokinetics and lower toxicity across patients. Uncontrolled products typically range from 1:2 to 1:10 CD4:CD8 depending on patient's pre-existing T-cell repertoire and manufacturing conditions. CD4+ CAR-T cells provide helper function while CD8+ cells are the primary effectors. PMID:32888407.",
    "biomarker_name": "CD4:CD8 Ratio in Product",
    "biomarker_type": "predictive",
    "assay_method": "Flow cytometry",
    "clinical_cutoff": "Defined 1:1 (liso-cel); variable for other products",
    "predictive_value": "Defined 1:1 ratio: CRS grade 3+ rate 2% vs 13-22% undefined",
    "associated_outcome": "Product consistency and predictable safety profile",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-il15-032",
    "text_summary": "Serum interleukin-15 (IL-15) is a homeostatic cytokine that rises after lymphodepleting chemotherapy and promotes CAR-T proliferation during the critical early expansion phase. Post-lymphodepletion IL-15 levels >100 pg/mL at day 0 (pre-infusion) correlate with superior CAR-T expansion (r=0.62, p=0.001). Flu/Cy lymphodepletion regimens produce higher IL-15 surges than Cy-only, which partly explains their superior efficacy. PMID:28622514.",
    "biomarker_name": "IL-15",
    "biomarker_type": "pharmacodynamic",
    "assay_method": "ELISA",
    "clinical_cutoff": ">100 pg/mL post-lymphodepletion (day 0)",
    "predictive_value": "IL-15 >100 pg/mL: correlation with Cmax (r=0.62, p=0.001)",
    "associated_outcome": "Homeostatic cytokine milieu supporting CAR-T expansion",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-ifng-033",
    "text_summary": "Interferon-gamma (IFN-gamma) is a key effector cytokine produced by activated CAR-T cells upon tumor engagement. Peak serum IFN-gamma levels correlate with both anti-tumor efficacy and CRS severity. In ZUMA-1, peak IFN-gamma was 10-fold higher in CR patients vs non-responders, but also 5-fold higher in grade 3-4 CRS vs grade 0-1 CRS. IFN-gamma >500 pg/mL at day 3 post-infusion predicts both response and toxicity risk. PMID:28622514.",
    "biomarker_name": "IFN-gamma",
    "biomarker_type": "pharmacodynamic",
    "assay_method": "Luminex multiplex",
    "clinical_cutoff": ">500 pg/mL at day 3 post-infusion",
    "predictive_value": "Peak IFN-gamma 10-fold higher in CR vs non-responders",
    "associated_outcome": "Dual indicator of anti-tumor activity and CRS risk",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "validated"
  },
  {
    "id": "biomarker-gmcsf-034",
    "text_summary": "Granulocyte-macrophage colony-stimulating factor (GM-CSF) produced by activated CAR-T cells drives monocyte/macrophage activation and contributes to CRS pathophysiology. GM-CSF neutralization (lenzilumab) in combination with CAR-T therapy reduced severe CRS incidence from 15% to 0% in the ZUMA-19 phase 1b study. GM-CSF knockout CAR-T cells (using CRISPR) maintain anti-tumor efficacy while reducing myeloid-mediated inflammatory toxicity in preclinical models. PMID:33462108.",
    "biomarker_name": "GM-CSF",
    "biomarker_type": "pharmacodynamic",
    "assay_method": "ELISA",
    "clinical_cutoff": ">200 pg/mL post-infusion",
    "predictive_value": "GM-CSF neutralization: 0% vs 15% severe CRS in ZUMA-19",
    "associated_outcome": "Myeloid-mediated CRS amplification and therapeutic target",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "emerging"
  },
  {
    "id": "biomarker-ang2vwf-035",
    "text_summary": "The angiopoietin-2 to von Willebrand factor (Ang-2/VWF) ratio is an emerging biomarker of endothelial activation that predicts severe neurotoxicity (ICANS) post-CAR-T therapy. Elevated Ang-2 reflects endothelial destabilization and blood-brain barrier (BBB) disruption, the key mechanism of ICANS pathophysiology. Ang-2/VWF ratio >1.5 pre-infusion identifies patients at high risk for grade >=3 ICANS with 80% sensitivity. This biomarker may guide prophylactic corticosteroid strategies. PMID:31235964.",
    "biomarker_name": "Angiopoietin-2/VWF Ratio",
    "biomarker_type": "predictive",
    "assay_method": "ELISA (dual analyte)",
    "clinical_cutoff": "Ang-2/VWF ratio >1.5",
    "predictive_value": "Sensitivity 80%, specificity 72% for grade 3+ ICANS",
    "associated_outcome": "Endothelial activation and severe neurotoxicity (ICANS) prediction",
    "target_antigen": "CD19",
    "disease": "DLBCL",
    "evidence_level": "emerging"
  }
]
